FEMASYS INC
About FEMASYS INC
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.3M
- Net income
- -$18.6M
- Total assets
- $20.7M
- Market cap
- $925.2K
- Gross margin
- 62.0%
- Operating margin
- -767.0%
- Net margin
- -812.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.3M
- Cost of revenue
- $872.4K
- Gross profit
- $1.4M
- Operating expenses
- $19.0M
- Operating income
- -$17.6M
- Income tax
- $1.3K
- Net income
- -$18.6M
- EPS (basic)
- $-0.47
- EPS (diluted)
- $-0.47
Balance sheet
- Total assets
- $20.7M
- Current assets
- $16.5M
- Total liabilities
- $14.9M
- Current liabilities
- $3.6M
- Shareholders’ equity
- $5.9M
Cash flow
- Operating cash flow
- -$18.7M
- Investing cash flow
- -$630.1K
- Financing cash flow
- $25.1M
- Net cash flow
- $5.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $925.2K
- EPS (diluted)
- $-0.47
- Shares outstanding
- 171.6K
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 18, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $18.6M in FY2025.
- Revenue grew 94% from FY2021 to FY2025.
- Gross margin of 62.0%, net margin -812.3%.
- Trading 77% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review FEMASYS INC.
Write a review
News about FEMASYS INC
News & sentiment via Polygon.io
